3E Bioventures

Matwings Technology is a biotechnology company specializing in the design of functionally optimized proteins through advanced evolutionary methods. Utilizing proprietary techniques, the company focuses on computational chemistry and artificial intelligence-driven drug molecular design. Matwings collaborates with major pharmaceutical firms to facilitate early-stage research and development of innovative drugs targeting complex and clinically valuable challenges. By leveraging its expertise, Matwings aims to achieve significant breakthroughs in drug formulation, enhancing the potential for new therapeutic solutions.

Rapafusyn Pharmaceuticals is a biotechnology company focused on developing innovative pharmaceuticals utilizing a unique class of natural product-like macrocycles. The company operates a pharmaceutical platform that enables healthcare professionals to generate libraries of hybrid macrocycles based on a bifunctional scaffold. By screening these libraries, Rapafusyn aims to identify lead compounds that can target both novel and established disease mechanisms. This approach is designed to address unmet medical needs and improve treatment options for patients suffering from various diseases.

Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.

Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.

Varnotech is a biotechnology company founded in 2019 that focuses on the development of vaccines, antibodies, and adjuvants aimed at combating various diseases and viruses. The company is dedicated to creating effective human vaccines and innovative adjuvants to enhance immune responses, thereby improving patient outcomes. Through its research and development efforts, Varnotech aims to address significant health challenges and contribute to global public health initiatives.

Myrobalan Therapeutics is a biotechnology company dedicated to developing oral neurorestorative therapies that aim to reverse key pathologies associated with brain dysfunctions and central nervous system (CNS) conditions. By leveraging a profound understanding of neurological processes such as demyelination and neuroinflammation, the company utilizes innovative drug discovery tools to create selective and brain-penetrant therapeutic candidates. This focus on addressing the underlying mechanisms of CNS disorders positions Myrobalan Therapeutics to meet significant unmet medical needs, thereby providing healthcare professionals with effective therapeutic options for a large patient population suffering from these conditions. The company's dedicated team of scientists is committed to advancing research and development efforts in the field of CNS therapies.

Jushu Biotech is a medical engineering company that focuses on the research and development of synthetic biosensing technology.

Smartlens is a clinical-stage Med Tech company focused on developing innovative technologies to diagnose and treat glaucoma, a leading cause of irreversible blindness. The company’s flagship product, miLens, is a novel eye pressure monitoring contact lens designed to provide a non-invasive and convenient solution for continuous intraocular pressure (IOP) monitoring. This technology addresses a critical need, as a significant portion of glaucoma patients remain undiagnosed, and many experience vision loss despite treatment. miLens utilizes a unique, electronics-free sensor technology, which is protected by an extensive portfolio of patents. In addition to IOP monitoring, Smartlens is exploring applications for its technology in neurological disorders and cancers at Stanford University Labs. The company also possesses a non-invasive drug delivery system that not only monitors IOP but also releases medication as needed, enhancing treatment efficacy and patient compliance. Smartlens has received recognition for its innovation, including awards for outstanding achievements in medical technology, and has been featured in various prominent media outlets.

Novlead Biotech is a company dedicated to enhancing human health through innovative medical technologies. It specializes in the development and manufacturing of medical devices that target cardiopulmonary, respiratory, and anti-infection applications. The company's primary focus is on the medical use of nitric oxide to address conditions such as pulmonary hypertension and infectious diseases. By leveraging its technological advancements, Novlead Biotech aims to improve treatment efficiency in hospitals and enhance the quality of life for patients.

Eaglenos is an IVD company that specialises in medical POCT, home health care devices, and health management systems. It focuses on chemistry, materials, electronics, software, machinery, and biomedical engineering. It helps in the advancement of electrochemistry, microfluidics, signal acquisition, and automation technologies.

Larkspur Biosciences is a biotechnology company dedicated to developing precision immunotherapies aimed at enhancing cancer treatment. The company focuses on understanding how tumors manipulate the immune system and seeks to address these challenges by targeting specific molecular characteristics of patient populations. Larkspur's innovative approach is designed to foster a robust and sustained immune response, particularly in colorectal cancer, while also exploring applications for other cancers. By aligning its therapies with the unique molecular profiles of tumors, Larkspur aims to improve treatment outcomes for patients facing the complexities of cancer.

Xunyuan Technology is a bio-refining and bio-manufacturing platform company based on non-grain carbon sources.

Eluminex Biosciences is engaged in the research, development, and commercialization of innovative therapies aimed at addressing unmet medical needs in ocular health. The company focuses on ophthalmology and tissue regeneration, leveraging recombinant human collagen to develop therapeutic solutions. Its pipeline includes treatments designed to slow and mitigate the effects of aging and overuse on vision, ultimately enabling healthcare providers to offer improved care to their patients. Through its commitment to advancing the field of ophthalmology, Eluminex Biosciences seeks to enhance diagnostic and therapeutic options for ocular illnesses.

Jushu Biotech is a medical engineering company that focuses on the research and development of synthetic biosensing technology.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, specializing in AI-powered medical imaging solutions. Founded in 2017, the company develops innovative software products such as SubtleMR and SubtlePET, which are designed to enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. These products utilize proprietary deep learning algorithms to reduce image noise and improve sharpness, thereby increasing efficiency and safety in clinical workflows. Subtle Medical's technology is FDA cleared and CE marked, and it operates on a vendor-agnostic AI infrastructure that integrates seamlessly with existing imaging systems. The company's mission is to enhance the quality, value, and accessibility of medical imaging by lowering costs, reducing imaging time, and minimizing radiation and contrast doses for patients.

Sipeng Technology is an innovative synthetic biology company specializing in the manufacturing of bio-based products. The firm develops advanced synthetic biology technologies, concentrating on the creation of negative carbon new materials, polymer monomers, and various high-value compounds. By leveraging its expertise, Sipeng Technology enables clients to access sustainable and eco-friendly bio-based solutions, contributing to the advancement of sustainable practices in various industries.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company founded in 2016 and located in Boston, Massachusetts. The company specializes in developing treatments for peripheral neuropathies, hemoglobinopathies, and specific oncology indications. Its innovative approach focuses on regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy's lead product, ricolinostat, serves as a selective HDAC6 inhibitor, which enables the treatment of conditions such as sickle cell disease and beta-thalassemia. Through its targeted therapeutic strategies, Regenacy aims to address significant unmet medical needs in various disease areas.

CytoNiche is a biotechnology company focused on the development of 3D micro-organization engineering technology, primarily for stem cell research. Originating from advancements at Tsinghua University, the company specializes in creating high-quality stem cell cultures and injectable 3D micro-tissue treatments. CytoNiche offers a range of innovative products and services, including automated and intelligent stem cell culture amplification processes and 3D cell high-throughput drug screening tools. Its solutions are designed to support research institutes, clinical organizations, stem cell companies, and drug research enterprises, providing reliable 3D micro-tissue products essential for advancing drug development and regenerative medicine.

Zhengli Technology specializes in the research, development, production, and sales of advanced invisible orthodontic products, dental restoration items, and professional dental software systems. The company aims to provide comprehensive, one-stop solutions for dental professionals both in China and globally. By focusing on innovative orthodontic appliances, Zhengli Technology enables patients to enhance their dental health and achieve straighter teeth, reflecting the company's commitment to improving dental care through technology and quality products.

Biosion is a biotech company focused on the development of biologics to treat resistant, relapsed, residual immune, and oncologic diseases.

ITabMed is a clinical-stage biotechnology company based in Shanghai, China, founded in 2020 as a spin-off from Generon BioMed Ltd. The company specializes in the research and development of immunotherapy drugs aimed at treating cancer. It has developed an immunotherapy antibody technology platform that has produced two products, A-319 and A-337, which are currently undergoing phase I clinical studies. Additionally, ITabMed is advancing multiple candidate drug molecules that are in various stages of preclinical development, demonstrating its commitment to innovation in cancer treatment.

Novlead Biotech is a company dedicated to enhancing human health through innovative medical technologies. It specializes in the development and manufacturing of medical devices that target cardiopulmonary, respiratory, and anti-infection applications. The company's primary focus is on the medical use of nitric oxide to address conditions such as pulmonary hypertension and infectious diseases. By leveraging its technological advancements, Novlead Biotech aims to improve treatment efficiency in hospitals and enhance the quality of life for patients.

Neural Galaxy is a brain science company that emerged from Harvard Medical School and the Massachusetts Institute of Technology. The organization focuses on addressing brain disorders through advanced software and hardware technologies. By leveraging breakthrough research in brain science, Neural Galaxy aims to enhance understanding of the brain and high-level intelligence. Its mission includes tackling significant challenges related to brain diseases and improving treatment options, ultimately contributing to a deeper comprehension of human cognition and enhancing overall societal intelligence.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

Cullgen Inc. is a biopharmaceutical company based in San Diego, California, founded in 2018. The company specializes in the development of innovative small molecule therapeutics aimed at treating diseases that currently lack effective therapeutic options, including cancer, inflammatory, and autoimmune diseases. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins, even those previously deemed undruggable. This approach enables the creation of first-in-class new chemical entities, providing scientists with novel methodologies for drug discovery and potentially transforming treatment paradigms for difficult-to-treat conditions.

Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, specializing in AI-powered medical imaging solutions. Founded in 2017, the company develops innovative software products such as SubtleMR and SubtlePET, which are designed to enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. These products utilize proprietary deep learning algorithms to reduce image noise and improve sharpness, thereby increasing efficiency and safety in clinical workflows. Subtle Medical's technology is FDA cleared and CE marked, and it operates on a vendor-agnostic AI infrastructure that integrates seamlessly with existing imaging systems. The company's mission is to enhance the quality, value, and accessibility of medical imaging by lowering costs, reducing imaging time, and minimizing radiation and contrast doses for patients.

Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for cancer and autoimmune diseases. Founded in 2000 and headquartered in Rockville, Maryland, the company has a diverse development portfolio that includes CD24Fc, a recombinant fusion protein designed for the prophylactic treatment of acute graft versus host disease, particularly in leukemia patients undergoing hematopoietic stem cell transplantation. Additionally, OncoImmune is developing sialidase inhibitors as a therapeutic strategy to prevent sepsis, ONC-392, a monoclonal antibody that aims to reduce immune-related toxicities while maintaining effective anti-tumor responses, and Echinomycin, a cyclic peptide formulation targeting acute myeloid leukemia. The company has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company founded in 2016 and located in Boston, Massachusetts. The company specializes in developing treatments for peripheral neuropathies, hemoglobinopathies, and specific oncology indications. Its innovative approach focuses on regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy's lead product, ricolinostat, serves as a selective HDAC6 inhibitor, which enables the treatment of conditions such as sickle cell disease and beta-thalassemia. Through its targeted therapeutic strategies, Regenacy aims to address significant unmet medical needs in various disease areas.

Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing antibody therapeutics for cancer treatment. Established in 2010, Apexigen specializes in immuno-oncology, creating therapies that aim to leverage the patient's immune system to effectively combat and eradicate cancer. The company's pipeline includes several promising candidates, such as APX005M and APX201 for immuno-oncology, along with additional programs targeting various oncology and inflammation conditions. Notably, its lead candidate, sotigalimab, is currently in clinical development, complemented by a range of preclinical immuno-oncology programs. Apexigen also utilizes its proprietary APXiMAB platform to discover novel antibodies targeting immune system pathways, underscoring its commitment to advancing innovative treatments in cancer care.

Lipidio Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego, California, focused on developing innovative therapeutics to address diseases associated with excess body fat. Founded in 2018, the company is advancing a lead candidate, GDD3898, for the treatment of various conditions, including Prader-Willi syndrome, nonalcoholic steatohepatitis, and antipsychotic drug-induced weight gain. In addition to its metabolic focus, Lipidio is also exploring applications for dermatological conditions such as sebaceous hyperplasia and moderate to severe acne. By targeting these medical needs, Lipidio Pharmaceuticals aims to provide effective treatment options for patients affected by obesity and related disorders.

Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat severe human diseases. The company specializes in host-directed anti-viral therapies aimed at addressing respiratory viral infections, such as influenza and parainfluenza viruses, by targeting the host rather than the virus itself. Its product pipeline includes Fludase, which is designed for the prophylaxis and treatment of influenza-related respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fever caused by pathogens like Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a technology for creating microspheres and nanospheres for drug delivery. Founded in 2003 and originally named NexBio, Inc., the company rebranded to Ansun Biopharma in 2011, reflecting its commitment to addressing critical health challenges through advanced biopharmaceutical solutions.

Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

Doctor Shaoyang operates a medical platform focused on delivering psychological and mental health support services. The company offers a range of services, including health consultations, doctor-patient communication, one-on-one appointment consultations, and pre-diagnosis. This platform facilitates seamless online communication between patients and doctors while ensuring the protection of sensitive information. By prioritizing accessibility and privacy, Doctor Shaoyang aims to enhance the overall experience for users seeking mental health support.

Medtrum Technologies Inc., established in 2008, specializes in developing and delivering medical devices for diabetes management. Its product portfolio includes the A6 TouchCare System, a tubing-free, semi-closed loop insulin management system that integrates an insulin patch pump and continuous glucose monitoring (CGM) with predictive low glucose suspend features. The S6 EasySense is a waterproof, disposable CGM system providing real-time glucose readings for a week. The P6 EasyPatch is a disposable insulin pump offering adjustable basal rates and bolus on demand. Medtrum's cloud-based healthcare system, comprising the EasyTouch mobile app and EasyView web portal, consolidates patient data for self-management, family support, and healthcare provider access. With headquarters in Shanghai, China, Medtrum also operates in Düsseldorf, Germany; Hong Kong; and Watford, UK.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment specifically designed for cancer and cell biology research. The company offers advanced flow cytometers, including the Cytek Aurora and Cytek Northern Lights, as well as the DxP Athena system, which utilizes proprietary technology to enhance the detection of dim populations in a multicolor format. In addition, Cytek provides the QbSure quality control program to ensure the optimal performance of its cytometers and a range of cFluor reagents tailored for use in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence internationally with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company was previously known as Cytoville, Inc. before rebranding in August 2015.

Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the design and development of tissue-integrated sensors and biosensors aimed at improving diabetes management. Founded in 2009, the company focuses on creating biointegrated sensors that allow individuals to monitor their biochemical data in real-time, facilitating better management of personal health and chronic diseases. Profusa's technology aims to seamlessly integrate with the body, providing continuous, clinical-grade data that enhances health outcomes. In addition to its sensor technology, the company has developed software that offers biofeedback to support chronic disease management and promote healthy living.

Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing antibody therapeutics for cancer treatment. Established in 2010, Apexigen specializes in immuno-oncology, creating therapies that aim to leverage the patient's immune system to effectively combat and eradicate cancer. The company's pipeline includes several promising candidates, such as APX005M and APX201 for immuno-oncology, along with additional programs targeting various oncology and inflammation conditions. Notably, its lead candidate, sotigalimab, is currently in clinical development, complemented by a range of preclinical immuno-oncology programs. Apexigen also utilizes its proprietary APXiMAB platform to discover novel antibodies targeting immune system pathways, underscoring its commitment to advancing innovative treatments in cancer care.

Ansun Biopharma, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies to prevent and treat severe human diseases. The company specializes in host-directed anti-viral therapies aimed at addressing respiratory viral infections, such as influenza and parainfluenza viruses, by targeting the host rather than the virus itself. Its product pipeline includes Fludase, which is designed for the prophylaxis and treatment of influenza-related respiratory infections, and Viradin, an intravenous therapeutic for sepsis and viral hemorrhagic fever caused by pathogens like Ebola and Marburg viruses. Additionally, Ansun Biopharma has developed TOSAP, a technology for creating microspheres and nanospheres for drug delivery. Founded in 2003 and originally named NexBio, Inc., the company rebranded to Ansun Biopharma in 2011, reflecting its commitment to addressing critical health challenges through advanced biopharmaceutical solutions.

Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.

Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

Eucure Biopharma, established in 2016 and headquartered in Beijing, China, is a biotechnology company focused on the discovery and development of innovative immuno-oncology targeted antibodies. Its pipeline comprises eight drug candidates, primarily targeting immune checkpoints, with several in the clinical trial application stage. The company offers services such as antibody production, in vivo and in vitro drug efficacy testing, and aims to improve the survival rate of tumor patients by developing effective antibody treatments.

Ligatech Bioscience, established in 2014 and headquartered in Qingpu, China, specializes in the design, development, production, and sales of medical devices for orthopedic and sports medicine. Its product portfolio includes molecular weight polyethylene suture and striped titanium plates, along with artificial ligaments and fixation systems. The company also offers technical advice and services to its users.

EpimAb Biotherapeutics, based in Shanghai, China, is a biopharmaceutical research and development company focused on creating innovative bispecific antibody therapeutics, particularly for immuno-oncology. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, EpimAb develops bispecific antibodies that combine the properties of two different monoclonal antibodies into a single molecule. This unique approach aims to address the limitations of traditional antibody therapies, offering potential solutions for various life-threatening diseases, including cancer. The company recognizes the challenges associated with developing bi-specific antibodies, such as maintaining their drug-like properties and ensuring adequate production. By advancing its pipeline of bispecific therapeutics, EpimAb seeks to meet the growing demand for effective treatment options in the pharmaceutical industry.

OncoImmune, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for cancer and autoimmune diseases. Founded in 2000 and headquartered in Rockville, Maryland, the company has a diverse development portfolio that includes CD24Fc, a recombinant fusion protein designed for the prophylactic treatment of acute graft versus host disease, particularly in leukemia patients undergoing hematopoietic stem cell transplantation. Additionally, OncoImmune is developing sialidase inhibitors as a therapeutic strategy to prevent sepsis, ONC-392, a monoclonal antibody that aims to reduce immune-related toxicities while maintaining effective anti-tumor responses, and Echinomycin, a cyclic peptide formulation targeting acute myeloid leukemia. The company has completed a Phase II clinical trial for CD24Fc and is preparing to initiate a pivotal trial for this indication.

MicuRx Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel antibiotics to combat drug-resistant bacterial infections. Founded in 2007 and based in Palo Alto, California, MicuRx operates with research and development facilities in both San Francisco, California, and Shanghai, China. The company's portfolio includes MRX-I, an oral antibiotic effective against multi-drug resistant gram-positive pathogens such as methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococci; MRX-IV, a water-soluble prodrug form of MRX-I for intravenous use; MRX-V, an injectable antibiotic targeting gram-negative bacteria; and MRX-VIII, a polymyxin for gram-negative infections. Additionally, MicuRx's pipeline includes other antibacterial drugs designed to combat both gram-positive and gram-negative bacterial pathogens. The company employs a hybrid U.S./China business model, leveraging U.S. research and development with cost-efficient scientific resources in China. Shanghai MicuRx commercializes the agent contezolid in China, while global clinical studies are ongoing.

Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.

Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the design and development of tissue-integrated sensors and biosensors aimed at improving diabetes management. Founded in 2009, the company focuses on creating biointegrated sensors that allow individuals to monitor their biochemical data in real-time, facilitating better management of personal health and chronic diseases. Profusa's technology aims to seamlessly integrate with the body, providing continuous, clinical-grade data that enhances health outcomes. In addition to its sensor technology, the company has developed software that offers biofeedback to support chronic disease management and promote healthy living.